Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients

Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer

(2011) Wells A. Messersmith et al.   Clinical Colorectal Cancer

Everolimus- and Temsirolimus-Associated Enteritis: Report of Three Cases

(2011) Kavitha Parithivel et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

(2011) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Fistulization Associated With Targeted Therapy

(2011) Henry Chow et al.   JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY

Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review

(2010) Maudy Walraven et al.   ANGIOGENESIS

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

(2010) D.L. Richardson et al.   GYNECOLOGIC ONCOLOGY

Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib

(2010) Romain Coriat et al.   INVESTIGATIONAL NEW DRUGS

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

(2009) Sanjaykumar Hapani et al.   LANCET ONCOLOGY